<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970957</url>
  </required_header>
  <id_info>
    <org_study_id>IOBA-03-2008</org_study_id>
    <secondary_id>EUDRA -CT 2008-005789-30</secondary_id>
    <nct_id>NCT00970957</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion</brief_title>
  <acronym>EBOVER</acronym>
  <official_title>Study of the Safety and Efficacy of Bevacizumab Intravitreal Injections for the Treatment of Macular Edema Secondary to Retinal Vein Occlusions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Universitario de Oftalmobiología Aplicada</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Universitario de Oftalmobiología Aplicada</source>
  <brief_summary>
    <textblock>
      Lack of an effective treatment for macular edema secondary to central retinal vein occlusion
      and the bad response to grid laser treatment in patients with macular edema secondary to
      branch retinal vein occlusion, together with the high incidence of the pathology and the
      great functional loss in the patients that suffer from it has motivated the search for new
      therapeutic approaches.

      In recent times, intravitreal bevacizumab has been tested in clinical practice in small
      series of patients with this pathology, whether as first treatment or after failure of grid
      laser treatment with good functional results in short series.

      However, no retreatment information is available, although preliminary results from published
      series are good.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity assessed as described in the Early Treatment for Diabetes Retinopathy Study (ETDRS)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Macular Subcentral Field Thickness assessed by Ocular coherence tomography</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Central RVO - Macular edema - Avastin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Central RVO - Macular edema - Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients with Macular edema secondary to CENTRAL Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Branch RVO - Macular edema - Avastin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will be treated with intravitreal injection of avastin once per month during the first 3 months. Re-treatments will be given as per protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Branch RVO - Macular edema - Sham</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients with Macular edema secondary to BRANCH Retinal Vein Occlusion that will have a sham procedure performed. Injection without needle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin Intravitreal Injection</intervention_name>
    <description>Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol</description>
    <arm_group_label>Central RVO - Macular edema - Avastin</arm_group_label>
    <arm_group_label>Branch RVO - Macular edema - Avastin</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sham Avastin Intravitreal Injection</intervention_name>
    <description>Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).</description>
    <arm_group_label>Central RVO - Macular edema - Sham</arm_group_label>
    <arm_group_label>Branch RVO - Macular edema - Sham</arm_group_label>
    <other_name>Sham</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient male or female 18 years old or more

          -  Foveal macular edema secondary to Retinal Vein Occlusion confirmed by Fluorescein
             angiography and Optical Coherence Tomography, with a subcentral field thickness of at
             least 250 microns

          -  Patients with best corrected visual acuity loss within the last 6 months of evolution,
             caused by the macular edema as stated by investigator´s judgement.

          -  Best corrected visual acuity tested by ETDRS within 20/40 and 20/400 in the study eye.

          -  Signed Informed consent.

          -  Signed Data Protection Consent.

          -  Negative pregnancy test before entering the study for childbearing potential women,
             who must commit to use a medically accepted contraceptive method for the whole study.

          -  Macular Subcentral field assessed by Ocular coherence tomography of at least 250
             microns thick.

          -  No presence of eye opacities that may prevent fundus exploration. No condition that
             may prevent correct eye dilation.

          -  No known allergy to fluorescein.

          -  Only an eye per patient will be included in the study,even if both eyes have the
             pathology.

        Exclusion Criteria:

          -  Macular edema secondary to any other condition such as: diabetes retinopathy,
             hypertension, Juxtafoveal telangiectasia, ...

          -  Any previous treatment for macular edema such as photocoagulation, vitrectomy,
             triamcinolone, radial optic neurotomy, ... in the study eye.

          -  Any ocular illness thay may be associated to increased/high levels of VEGF (Age
             related macular degeneration, Diabetes retinopathy, Uveitis, ...)

          -  Systemical illnesses thay may be associated to increased/high levels of VEGF (e.g.
             tumours).

          -  Medical history of brain vascular episodes (stroke), ictus, angor pectoris or
             myocardial infarct within 3 months before study inclusion.

          -  Pregnancy or nursing.

          -  Hypersensibility known or suspected to Bevacizumab, his excipients or any related
             molecule.

          -  Uncontrolled hypertension refractary to medical treatment.

          -  Participation in any other trial or study within the last 3 months (minerals and
             vitamins excluded) or treatment with anti-VEGF in the non-study eye within the
             previous 3 months.

          -  Tractional maculopathy and/or epiretinal membrane assessed by Ocular Coherence
             Tomography.

          -  Media opacities that don´t allow correct eye exploration and fundus
             examination/photographs.

          -  Cataract surgery / Yag capsulotomy within the previous 6 months.

          -  Filtration surgery.

          -  Previous medical history of ocular illnesses as: viral infections, inflammatory
             pathology, serous central choroidopathy, retinal detachment or any other illness that
             may have an influence in visual acuity.

          -  Presence of foveal atrophy, severe pigmentary changes, dense subfoveal haemorrhages,
             confluent subfoveal hard exudates or any other condition that may influence functional
             recovery of the macular edema.

          -  Cataract that may be responsible for additional visual acuity loss of more than 2/10.

          -  Medically uncontrolled intraocular pressure higher than 25 mm Hg.

          -  External ocular illnesses active at inclusion as: conjunctivitis, blepharitis, eye
             sore, ...
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María Isabel López Gálvez, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IOBA - Instituto Universitario de Oftalmobiología Aplicada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Provincial Conxo - Fundación IDICHUS</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Reina Sofía</name>
      <address>
        <city>Espinardo</city>
        <state>Murcia</state>
        <zip>30100</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31080</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Oftalmológico de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Vall D´Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Universitario de Oftalmobiología Aplicada</name>
      <address>
        <city>Valladolid</city>
        <zip>47011</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <last_update_submitted>March 18, 2014</last_update_submitted>
  <last_update_submitted_qc>March 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macular edema</keyword>
  <keyword>Retinal Vein Occlusion</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

